Zimmer Biomet Holdings ( (ZBH) ) has released its Q2 earnings. Here is a breakdown of the information Zimmer Biomet Holdings presented to its investors.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Zimmer Biomet Holdings, Inc., a leading global medical technology company, specializes in providing innovative solutions to enhance mobility and improve health through its comprehensive portfolio of orthopedic and surgical products, including integrated digital and robotic technologies.
In its latest earnings report, Zimmer Biomet announced a strong financial performance for the second quarter of 2025, with net sales reaching $2.077 billion, marking a 7.0% increase from the previous year. The company also reported adjusted diluted earnings per share of $2.07, reflecting a 3.0% growth.
Key highlights from the report include a significant boost in the U.S. Hips and Knees portfolios, driven by a robust new product cycle, and continued growth in the global S.E.T. business. Additionally, Zimmer Biomet has entered into a definitive agreement to acquire Monogram Technologies, an AI-driven robotics company, and has formed a strategic partnership with Getinge to distribute operating room products.
Looking ahead, Zimmer Biomet has tightened its full-year 2025 revenue growth guidance to 6.7% – 7.7% and increased its adjusted earnings per share guidance to $8.10 – $8.30. The company remains optimistic about its growth prospects, driven by customer-centric innovation and strategic acquisitions.